How many MDxHealth share options were granted to director Sanford Jay Siegel?

Sanford Jay Siegel was granted options on 10,000 MDxHealth ordinary shares. This derivative award increases his potential equity exposure, giving him the right to acquire those shares if he chooses to exercise the options in the future.

What is the exercise price of Sanford Jay Siegel’s MDxHealth share options?

The options granted to Sanford Jay Siegel have an exercise price of $0.76 per ordinary share. This strike price is the amount he must pay per share if he exercises the options to acquire MDxHealth stock.

When do Sanford Jay Siegel’s MDxHealth share options expire?

These MDxHealth share options expire on May 28, 2036. After that expiration date, the rights to purchase the underlying ordinary shares at the $0.76 exercise price lapse and can no longer be used.

MDxHealth (MDXH) director granted options on 10,000 shares

Q: When do Sanford Jay Siegel’s MDxHealth share options vest?

The 10,000 MDxHealth share options vest in full on the date of the annual general shareholders' meeting held in the calendar year after the grant year. Vesting must occur before the options can be exercised.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

MDxHealth SA director Sanford Jay Siegel received a grant of share options covering 10,000 ordinary shares. The options have an exercise price of $0.76 per share and were granted as compensation. They vest in full at the annual general shareholders' meeting held in the calendar year after the grant.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Siegel Sanford Jay

Role null

Type	Security	Shares	Price	Value
Grant/Award	Share Option	10,000	$0.00	--

Holdings After Transaction: Share Option — 10,000 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

Options granted: 10,000 options Underlying shares: 10,000 ordinary shares Exercise price: $0.76 per share +3 more

6 metrics

Options granted 10,000 options Share options granted to director on ordinary shares

Underlying shares 10,000 ordinary shares Shares subject to the granted options

Exercise price $0.76 per share Option strike price for the grant

Expiration date May 28, 2036 Option expiration for this grant

Post-grant derivative holdings 10,000 options Total options held following this transaction

Vesting condition Next AGM after grant year Vests at annual general shareholders' meeting

Key Terms

Share Option, Ordinary Shares, exercise price, annual general shareholders' meeting

4 terms

Ordinary Shares financial

"underlying_security_title: "Ordinary Shares""

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

exercise price financial

"price per share of $0.76 granted on June 1, 2026"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

annual general shareholders' meeting financial

"vest in full on the date of the annual general shareholders' meeting"

A yearly meeting where a company’s shareholders and board of directors come together to review performance, vote on key issues (such as electing directors and approving auditors), and ask questions of management. Think of it like a town-hall or annual check-in where owners can influence how the company is run; outcomes can affect governance, dividend decisions and long-term strategy, all of which can influence the value and risks of an investor’s holdings.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

06/03/2026 - 05:30 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Siegel Sanford Jay

(Last)

(First)

(Middle)

CAP BUSINESS CENTER

ZONE INDUSTRIELLE DES HAUTS-SARTS

(Street)

HERSTAL

BELGIUM

4040

(City)

(State)

(Zip)

BELGIUM

(Country)

2. Issuer Name and Ticker or Trading Symbol
MDxHealth SA [ MDXH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Share Option	$0.76	06/01/2026		A		10,000		⁽¹⁾	05/28/2036	Ordinary Shares	10,000	$0	10,000	D

Explanation of Responses:

1. Represents options to purchase 10,000 ordinary shares of the Issuer at a price per share of $0.76 granted on June 1, 2026 which vest in full on the date of the annual general shareholders' meeting that takes place in the calendar year following the calendar year in which the options were granted.

	/s/ Mark Busch, as attorney-in-fact for Sanford Jay Siegel	06/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did MDxHealth (MDXH) report for Sanford Jay Siegel?

MDxHealth reported that director Sanford Jay Siegel received a grant of share options. The award covers 10,000 ordinary shares, providing equity-based compensation that aligns his interests with shareholders through potential future share ownership.

Does this MDxHealth Form 4 show a market purchase or sale of shares?

No, the Form 4 shows a grant of derivative securities, specifically share options, to Sanford Jay Siegel. It is a compensation-related acquisition rather than an open-market purchase or sale of MDxHealth ordinary shares.